Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma
Current Oncology · 2024
DOI: 10.3390/curroncol31080315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Teiji Kuzuya und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake 470-1192, Japan. Hauptthemen laut MEDLINE: alpha-Fetoproteins, Carcinoma, Hepatocellular, Prothrombin, Liver Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The relationship between antitumor response and tumor marker changes was evaluated in patients with advanced hepatocellular carcinoma treated with durvalumab plus tremelimumab (Dur/Tre). Forty patients were enrolled in this retrospective evaluation of treatment outcomes. According to the Response Evaluation Criteria for Solid Tumors version 1.1 at 8 weeks, the objective response (OR) rate was 25% and the disease control (DC) rate was 57.5%. The median alpha-fetoprotein (AFP) ratio at 4 weeks was 0.39 in patients who achieved OR at 8 weeks (8W-OR group), significantly lower than the 1.08 in the non-8W-OR group (p = 0.0068); however, it was 1.22 in patients who did not achieve DC at 8 weeks (non-8W-DC group), significantly higher than the 0.53 in the 8W-DC group (p = 0.0006). Similarly, the median des-γ-carboxy-prothrombin (DCP) ratio at 4 weeks was 0.15 in the 8W-OR group, significantly lower than the 1.46 in the non-8W-OR group (p < 0.0001); however, it was 1.23 in the non-8W-DC group, significantly higher than the 0.49 in the 8W-DC group (p = 0.0215). Early changes in tumor markers after Dur/Tre initiation were associated with antitumor response. In particular, changes in AFP and DCP at 4 weeks may offer useful biomarkers for early prediction of both response and progressive disease following Dur/Tre.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake 470-1192, Japan.
ORCID-Profile: Teiji Kuzuya, Kazunori Nakaoka, Kohei Funasaka, Yoshiki Hirooka
Zitieren
APA
Kuzuya, T., Kawabe, N., Muto, H., Wada, Y., Komura, G., Nakano, T., Tanaka, H., Nakaoka, K., Ohno, E., Funasaka, K., Nagasaka, M., Miyahara, R., & Hirooka, Y. (2024). Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma. Current Oncology. https://doi.org/10.3390/curroncol31080315
Vancouver
Kuzuya T, Kawabe N, Muto H, Wada Y, Komura G, Nakano T, et al. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma. Current Oncology. 2024. doi:10.3390/curroncol31080315
BibTeX
@article{Kuzuya2024,
author = {Kuzuya, Teiji and Kawabe, Naoto and Muto, Hisanori and Wada, Yuryo and Komura, Gakushi and Nakano, Takuji and Tanaka, Hiroyuki and Nakaoka, Kazunori and Ohno, Eizaburo and Funasaka, Kohei and Nagasaka, Mitsuo and Miyahara, Ryoji and Hirooka, Yoshiki},
title = {Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31080315}
}
EUVIMED